Coca-Cola FEMSA, S.A.B. de C.V. (KOF) At $68.77 Forms Bottom; Shorts at Mei Pharma (MEIP) Raised By 2.21%

Coca-Cola FEMSA, S.A.B. de C.V. (KOF) formed multiple bottom with $64.64 target or 6.00% below today’s $68.77 share price. Coca-Cola FEMSA, S.A.B. de C.V. (KOF) has $14.45B valuation. The stock decreased 0.55% or $0.38 during the last trading session, reaching $68.77. About 71,145 shares traded. Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:KOF) has declined 2.10% since March 13, 2017 and is downtrending. It has underperformed by 18.80% the S&P500.

Mei Pharma Inc (NASDAQ:MEIP) had an increase of 2.21% in short interest. MEIP’s SI was 69,400 shares in March as released by FINRA. Its up 2.21% from 67,900 shares previously. With 96,900 avg volume, 1 days are for Mei Pharma Inc (NASDAQ:MEIP)’s short sellers to cover MEIP’s short positions. The SI to Mei Pharma Inc’s float is 0.21%. The stock decreased 1.85% or $0.04 during the last trading session, reaching $2.12. About 54,298 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since March 13, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Wednesday, May 31 with “Buy” rating. The stock has “Hold” rating by Wedbush on Friday, September 4. Oppenheimer maintained the shares of MEIP in report on Wednesday, June 14 with “Buy” rating. On Monday, June 26 the stock rating was maintained by Oppenheimer with “Buy”. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) has “Hold” rating given on Wednesday, September 6 by Stifel Nicolaus. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Wednesday, August 2 with “Buy” rating.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $78.55 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

Among 7 analysts covering Coca-Cola FEMSA (NYSE:KOF), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Coca-Cola FEMSA had 18 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:KOF) has “Overweight” rating given on Friday, May 12 by JP Morgan. The rating was downgraded by Goldman Sachs to “Neutral” on Monday, January 18. As per Friday, November 17, the company rating was downgraded by Credit Suisse. The firm has “Outperform” rating given on Thursday, September 8 by Credit Suisse. The firm has “Reduce” rating given on Monday, January 11 by Nomura. The firm has “Overweight” rating given on Monday, March 7 by Barclays Capital. The firm earned “Neutral” rating on Friday, June 3 by JP Morgan. The firm has “Overweight” rating by Barclays Capital given on Friday, October 14. Goldman Sachs downgraded the stock to “Neutral” rating in Friday, January 15 report. On Friday, September 11 the stock rating was downgraded by Santander to “Hold”.